Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Articles published by Spectrum Pharmaceuticals, Inc.

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Announces Management Changes
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™ (eflapegrastim-xnst) Injection
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2022
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR Annual Meeting
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Corporate Update
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Announces an Oral Poziotinib Presentation at the Upcoming ESMO TAT 2022 Virtual Meeting
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharmaceutical
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Spectrum Pharmaceuticals Announces Changes to Management Team and Board of Directors
From Spectrum Pharmaceuticals, Inc.
Via Business Wire
Tickers SPPI
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.